Reckitt Benckiser Agrees to Acquire Paras

By Actis Llp, PRNE
Saturday, December 11, 2010

MUMBAI and LONDON, December 13, 2010 - Reckitt Benckiser Group plc ('RB') and Actis announced today that RB has
agreed to acquire Paras Pharmaceuticals Limited, a leading Indian FMCG
personal care company, for approximately INR 32.6 billion (approximately

The emerging markets private equity investor Actis will sell its 63%
holding in Paras to RB. Sequoia Capital and the remaining shareholders,
including Paras founder Girish Patel and his family, will also sell their
shares to RB.

Paras (FY10 net sales of INR 4,014 million and EBITDA for the same year
of INR 1,083 million) is the home to many of India's flagship
over-the-counter brands, including Moov pain relief ointment, Krack heel care
lotion, and D'Cold cold remedy. These long-standing and respected Indian
health care brands will join the existing RB family, which includes Dettol,
Disprin, Clearasil, Veet and Durex.

Commenting on the sale, Paul Fletcher, Senior Partner of Actis said, "For
us this is a classic story of Actis's commitment to building sustainable
value. Since our initial investment in Paras in 2006, we have used our
capital, consumer insights, operational expertise and local networks to
transform the company into a world-class player delivering market-leading
growth. We have built on the distinguished legacy of the Founder Girish
, in partnership with the management team, to create an organisation
that will sit well alongside a leading global company like Reckitt Benckiser.
We are delighted with this result."

JM Trivedi, Actis Partner and Head of South Asia, said, "Paras has been a
great example of Actis's ability to create value through a synergistic
relationship between the entrepreneur-founder Girish Patel, a private equity
investor, and a professional management team led by CEO S Raghunandan. Our
Indian consumer insights at Actis have proved to be first class. Reckitt
Benckiser is a natural home for the much-loved brands of Paras."

Paras Founder and Chairman Girish Patel, who will sell his family's stake
in the business as part of this transaction, expressed his support for the
decision saying, "We have been on a rewarding journey with Actis and the
quality of our partnership has proved to be the key reason for the recent
success of the company. We are very pleased with this outcome. I am now very
happy to hand over the 25 year old legacy of Paras to RB. I believe RB will
take our already strong brands to the next level, while also providing our
high quality management team with the opportunity for further development."

Bart Becht, CEO of RB, welcomed the deal, saying, "The acquisition of
Paras is another step forward in RB's growth strategy in consumer health
care. It creates a material health care business in India, one of the most
promising health care markets in the world with the addition of number of
strong and leading brands."

Chander Sethi, President of South Asia for RB, commented, "The Paras
brands are well known throughout India. They include products that many
Indian consumers know and love. Combined with RB's investment, global
innovation and distribution capabilities, the Paras health care portfolio
gives RB a platform for exciting new growth in India, in addition to
attractive cost synergies. Girish Patel has created a set of highly
successful and admired brands in the Indian market and we will build upon his

RB was advised by JPMorgan. Actis and the other Paras shareholders were
advised by Morgan Stanley.

About Actis

Actis is a leading private equity investor in the emerging markets with a
growing portfolio of investments in Asia, Africa and Latin America. It
currently has US$4.7bn funds under management and over 100 investment
professionals on the ground in 9 offices worldwide.

Actis is committed to promoting the sustainable growth of the private
sector in the emerging markets. Its aim is to ensure that the capital it
raises and manages makes a lasting, tangible and positive difference in the
countries in which it operates by creating opportunities for the companies in
which it invests, as well as their stakeholders.

About Reckitt Benckiser ('RB')

RB is a world leader in household, health and personal care.

Listed on the UK's London Stock Exchange, it is a FTSE top 25 company and
since 2000 net revenues have doubled and the market cap has quadrupled.
Today, it is the global No 1 or No 2 in the majority of its fast-growing
categories, driven by an exceptional rate of innovation - typically about 35%
of net revenue comes from innovations launched in the prior 3 years. It has a
strong portfolio led by 19 global powerbrands which are: Finish, Lysol,
Dettol, Vanish, Woolite, Durex, Calgon, Airwick, Harpic, Bang, Mortein, Veet,
Nurofen, Clearasil, Strepsils, Gaviscon, Mucinex, Scholl and French's.

RB people are at the heart of the company's success. They have an intense
drive for progress and action and a desire to outperform wherever they focus,
including in CSR where the company has the most ambitious corporate
responsibility programme in the industry through its Carbon 20 initiative.

Headquartered in the United Kingdom, the company employs about 25,000
people worldwide, with operations in over 60 countries and sales in almost
200 countries.

For more information:

Reckitt Benckiser:

Jo Speed (Investor Relations): +44-1753-217-800

David Litterick/Teresa Bianchi (Brunswick) (Media): +44-20-7404-5959


Ravi Shyam: +91-982-996-2496 (Mumbai)

Claire Davies +44-207-234-5115 (London)

For more information: Reckitt Benckiser: Jo Speed (Investor Relations): +44-1753-217-800; David Litterick/Teresa Bianchi (Brunswick) (Media): +44-20-7404-5959; Actis: Ravi Shyam: +91-982-996-2496 (Mumbai); Claire Davies +44-207-234-5115 (London)

will not be displayed